Companies › BioRay Pharmaceutical
4 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 2, 1 Phase 3; Oncology, Genitourinary; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Trastuzumab (HS627) Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 3 | Breast Cancer | – |
| Rituximab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 2 | Primary Membranous Nephropathy | Mar 2027 |
| BR111-101 for injection | – | Phase 1 | Advanced Malignancies | Oct 2027 |
| BRY812 for injection | – | Phase 1 | Advanced Malignancies | Aug 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04514419 | Trastuzumab (HS627) | Phase 3 | Breast Cancer | Oncology | Sep 2024 |
| NCT06642909 | Rituximab | Phase 2 | Primary Membranous Nephropathy | Genitourinary | Mar 2027 |
| NCT06937957 | BR111-101 for injection | Phase 1 | Advanced Malignancies | Oncology | Oct 2027 |
| NCT06038058 | BRY812 for injection | Phase 1 | Advanced Malignancies | Oncology | Aug 2028 |
Roche Beijing Biotech Biocad Shanghai Henlius Biotech Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical AstraZeneca Acerta Pharma Shanghai JMT-Bio R-Pharm
SystImmune DualityBio Aston Sci. Chengdu SciMount Pharmatech CSPC Megalith Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.